DIVA Laboratories Ltd (4153) - Total Assets
Based on the latest financial reports, DIVA Laboratories Ltd (4153) holds total assets worth NT$1.35 Billion TWD (≈ $42.65 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 4153 net assets for net asset value and shareholders' equity analysis.
DIVA Laboratories Ltd - Total Assets Trend (2017–2025)
This chart illustrates how DIVA Laboratories Ltd's total assets have evolved over time, based on quarterly financial data.
DIVA Laboratories Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
DIVA Laboratories Ltd's total assets of NT$1.35 Billion consist of 80.1% current assets and 19.9% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 36.5% |
| Accounts Receivable | NT$285.50 Million | 21.1% |
| Inventory | NT$249.82 Million | 18.5% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$996.00K | 0.1% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how DIVA Laboratories Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is DIVA Laboratories Ltd worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: DIVA Laboratories Ltd's current assets represent 80.1% of total assets in 2025, an increase from 68.2% in 2017.
- Cash Position: Cash and equivalents constituted 36.5% of total assets in 2025, up from 26.5% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 1.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 21.1% of total assets.
DIVA Laboratories Ltd Competitors by Total Assets
Key competitors of DIVA Laboratories Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$17.03 Billion |
|
Eurofins-Cerep SA
PA:ALECR
|
France | €84.58 Million |
|
Inoviq Ltd
AU:IIQ
|
Australia | AU$24.52 Million |
|
Bcal Diagnostics Ltd
AU:BDX
|
Australia | AU$7.17 Million |
|
Imagion Biosystems Ltd
AU:IBX
|
Australia | AU$932.48K |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
|
Australian Clinical Labs Ltd
AU:ACL
|
Australia | AU$562.50 Million |
|
Monash Ivf Group Ltd
AU:MVF
|
Australia | AU$510.21 Million |
DIVA Laboratories Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.35 | 4.18 | 6.45 |
| Quick Ratio | 2.58 | 3.56 | 4.41 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$760.92 Million | NT$784.13 Million | NT$668.81 Million |
DIVA Laboratories Ltd - Advanced Valuation Insights
This section examines the relationship between DIVA Laboratories Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.87 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | 3.7% |
| Total Assets | NT$1.35 Billion |
| Market Capitalization | $56.56 Million USD |
Valuation Analysis
Below Book Valuation: The market values DIVA Laboratories Ltd's assets below their book value (0.04x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: DIVA Laboratories Ltd's assets grew by 3.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for DIVA Laboratories Ltd (2017–2025)
The table below shows the annual total assets of DIVA Laboratories Ltd from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | NT$1.35 Billion ≈ $42.65 Million |
+3.69% |
| 2024-12-31 | NT$1.31 Billion ≈ $41.13 Million |
+4.96% |
| 2023-12-31 | NT$1.24 Billion ≈ $39.18 Million |
-0.64% |
| 2022-12-31 | NT$1.25 Billion ≈ $39.44 Million |
+5.93% |
| 2021-12-31 | NT$1.18 Billion ≈ $37.23 Million |
+6.15% |
| 2020-12-31 | NT$1.11 Billion ≈ $35.07 Million |
-14.46% |
| 2019-12-31 | NT$1.30 Billion ≈ $41.00 Million |
-1.62% |
| 2018-12-31 | NT$1.32 Billion ≈ $41.68 Million |
+24.61% |
| 2017-12-31 | NT$1.06 Billion ≈ $33.45 Million |
-- |
About DIVA Laboratories Ltd
DIVA Laboratories, Ltd. engages in the development, manufacture, and sale of medical equipment and computer related devices worldwide. The company provides endo/surgical displays, a static and dynamic image for hybrid and integrated ORs applications; color and mono displays for radiology and medical imaging applications; touch displays/human machine interface products; medical and industrial case… Read more